Advertisement
Screener

CHAMPIONS ONCOLOGY, INC. (CSBR) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

2.8 / 5 stars · 68/120 Roast Me

CHAMPIONS ONCOLOGY, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

CHAMPIONS ONCOLOGY, INC. (CSBR) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 0.00% for the 3-month period ending 2025-10-31, per its 10-Q filed 2025-12-15.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2025-12-15

  • CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-10-31 was 0.00%.
  • CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-07-31 was 62.72%, a 0.18% decline year-over-year.
  • CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-01-31 was 63.41%, a 2.47% increase year-over-year.
  • CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-10-31 was 63.30%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month as first filedShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month
2025-10-310.00%
10-Q · filed 2025-12-15
2024-07-3162.72%
10-Q · filed 2025-09-15
2024-01-3163.41%
10-Q · filed 2025-03-17
2023-10-3163.30%
10-Q · filed 2024-12-16
2023-07-3162.83%
10-Q · filed 2024-09-13
2023-01-3161.88%
10-Q · filed 2024-03-15
2022-10-310.00%
10-Q · filed 2023-12-13
62.58%
10-Q · filed 2023-12-13
2021-01-3174.98%
10-Q · filed 2022-03-15
2020-10-3172.83%
10-Q · filed 2021-12-13
2020-07-3172.64%
10-Q · filed 2021-09-13
2019-10-3171.11%
10-Q · filed 2020-12-14
71.11%
10-Q · filed 2020-12-14
2019-07-310.00%
10-Q · filed 2020-09-14
2018-10-3183.88%
10-Q · filed 2019-12-16
2018-07-3184.40%
10-Q · filed 2019-09-16
2018-01-3185.60%
10-Q · filed 2019-03-18
85.59%
10-Q · filed 2018-03-19
2017-10-310.00%
10-Q · filed 2018-12-17
87.10%
10-Q · filed 2017-12-15
87.10%
10-Q · filed 2018-12-17
2017-07-3187.10%
10-Q · filed 2018-09-14
2015-01-310.00%
10-Q · filed 2016-03-16

Similar stocks

Stock NameCountryMarket CapPE Ratio
BioStem Technologies, Inc. (BSEM)United States$0.069B
Kalaris Therapeutics, Inc. (KLRS)United States$0.073B-2.19
Eloxx Pharmaceuticals, Inc. (ELOX)United States$0.065B
MiNK Therapeutics, Inc. (INKT)United States$0.063B-5.37
Vaxart, Inc. (VXRT)United States$0.080B3.84
EXOZYMES INC. (EXOZ)United States$0.058B
BioAtla, Inc. (BCAB)United States$0.058B-0.21
ImageneBio, Inc. (IMA)United States$0.056B-1.31
Inmune Bio, Inc. (INMB)United States$0.056B-2.48
Atara Biotherapeutics, Inc. (ATRA)United States$0.086B-6.48